Fluidigm Corp (FLDM)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Fluidigm Corp (FLDM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014317
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Fluidigm Corp (Fluidigm) formerly known as Mycometrix Corporation, is a biotechnology company which manufactures life-science tools and creates technologies based on microfluidics and mass cytometry. The company’s products systems include biomark HD system, access array system, C1 system, callisto system, EP1 system, polaris system, juno system, and helios. It also provides custom assays such as SNP type assays, maxplar antibodies, delta gene assays and access array assays. Fluidigm offers software, which include fluidigm cytobank analysis, singular analysis toolset, SNP genotyping analysis, real-time PCR analysis, and digital PCR analysis. The company’s C1 system supports mRNA sequencing, DNA sequencing, miRNA analysis and additional applications through the C1 open app IFC. It has operations in France, Canada, Singapore, China, Japan, Australia, the UK and Germany. Fluidigm is headquartered in South San Francisco, California, the US.

Fluidigm Corp (FLDM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Fluidigm Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Fluidigm Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Fluidigm Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Fluidigm Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Fluidigm Corp, Medical Devices Deals, 2011 to YTD 2017 10
Fluidigm Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Fluidigm Corp, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Fluidigm Enters Into Co-Marketing Agreement With Olink Bioscience For Protein Biomarkers 12
Fluidigm Enters Into Co-Development Agreement With DKMS For High Throughput HLA Typing System 14
Genome Institue of Singapore Partners With Fluidigm To Establish Single-Cell Genomics Research Center 15
DVS Sciences And Cytobank Enter Into Co-Development Agreement 16
Equity Offering 17
Fluidigm Raises USD30 Million in Public Offering of Shares 17
Fluidigm Completes Public Offering Of Common Stock For US$60 Million 18
Fluidigm Completes IPO Of Common Stock For US$86.3 Million 20
Debt Offering 22
Fluidigm Completes Public Offering Of Notes Due 2034 For US$201.3 Million 22
Fluidigm Corp – Key Competitors 24
Fluidigm Corp – Key Employees 25
Fluidigm Corp – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Strategy And Business Planning 27
Aug 04, 2016: Fluidigm Introduces New High-Throughput Targeted NGS Library Preparation System 27
Jun 09, 2016: Fluidigm Announces New Customer Inspiration Center in Canada for Mass Cytometry 28
Financial Announcements 29
Nov 02, 2017: Fluidigm Announces Third Quarter Financial Results and Operational Progress 29
May 04, 2017: Fluidigm Announces First Quarter Financial Results 31
Feb 08, 2017: Fluidigm Announces Q4 And Full Year 2016 Financial Results 34
Jan 09, 2017: Fluidigm Announces Preliminary Revenue For The Fourth Quarter And Full Year 36
Nov 03, 2016: Fluidigm Announces Third Quarter Financial Results 37
Oct 12, 2016: Fluidigm Announces Preliminary Third Quarter 2016 Revenue 39
Aug 04, 2016: Fluidigm Announces Q2 2016 Financial Results 40
May 05, 2016: Fluidigm Announces First Quarter Financial Results 42
Feb 04, 2016: Fluidigm Announces Q4-Full Year 2015 Financial Results 44
Jan 12, 2016: Fluidigm Announces Preliminary Full Year and Fourth Quarter 2015 Revenue 45
Corporate Communications 46
Mar 27, 2017: Nicolas Barthelemy and Carlos Paya Join Fluidigm Board of Directors 46
Oct 19, 2016: Fluidigm Names S. Christopher Linthwaite as New Chief Executive Officer 47
Aug 04, 2016: Fluidigm Appoints New President and Chief Operating Officer 48
Legal and Regulatory 49
Aug 04, 2016: Fluidigm Receives ISO 13485 And ISO 9001 Certification 49
Product News 50
Dec 21, 2016: Fluidigm Introduces A New Medium-Cell High-Throughput Integrated Fluidic Circuit 50
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51

List of Tables
Fluidigm Corp, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Fluidigm Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Fluidigm Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Fluidigm Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Fluidigm Corp, Deals By Therapy Area, 2011 to YTD 2017 9
Fluidigm Corp, Medical Devices Deals, 2011 to YTD 2017 10
Fluidigm Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Fluidigm Enters Into Co-Marketing Agreement With Olink Bioscience For Protein Biomarkers 12
Fluidigm Enters Into Co-Development Agreement With DKMS For High Throughput HLA Typing System 14
Genome Institue of Singapore Partners With Fluidigm To Establish Single-Cell Genomics Research Center 15
DVS Sciences And Cytobank Enter Into Co-Development Agreement 16
Fluidigm Raises USD30 Million in Public Offering of Shares 17
Fluidigm Completes Public Offering Of Common Stock For US$60 Million 18
Fluidigm Completes IPO Of Common Stock For US$86.3 Million 20
Fluidigm Completes Public Offering Of Notes Due 2034 For US$201.3 Million 22
Fluidigm Corp, Key Competitors 24
Fluidigm Corp, Key Employees 25
Fluidigm Corp, Other Locations 26
Fluidigm Corp, Subsidiaries 26

★海外企業調査レポート[Fluidigm Corp (FLDM)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • AECOM (ACM):電力:M&Aディール及び事業提携情報
    Summary AECOM, formerly AECOM Technology Corporation, is a provider of engineering, consulting and project management services. The company primarily designs, builds, operates and finances various infrastructure assets for businesses, governments, and organizations. Its service offerings include ass …
  • Ormat Technologies Inc (ORA):企業の財務・戦略的SWOT分析
    Ormat Technologies Inc (ORA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Taisei Corporation:企業の戦略・SWOT・財務情報
    Taisei Corporation - Strategy, SWOT and Corporate Finance Report Summary Taisei Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Grupa Azoty SA (ATT):企業の財務・戦略的SWOT分析
    Grupa Azoty SA (ATT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • In-N-Out Burgers:企業の戦略・SWOT・財務情報
    In-N-Out Burgers - Strategy, SWOT and Corporate Finance Report Summary In-N-Out Burgers - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Collagen Solutions Plc (COS):製品パイプライン分析
    Summary Collagen Solutions Plc (Collagen Solutions), formerly Healthcare Investment Opportunities Plc is a medical device company that develops, manufactures and supplies medical grade collagen biomaterials and components. The company offers sourcing and supply of high grade collagen; provision of f …
  • Corning Incorporated (GLW)-エネルギー分野:企業M&A・提携分析
    Summary Corning Incorporated (Corning) manufactures and sells ceramics, specialty glasses and related materials. The company’s product portfolio includes glass substrates, which find application in LCD televisions, computer monitors and laptops; optical fibers, cable, hardware and equipment for tele …
  • Taiho Pharmaceutical Co Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Taiho Pharmaceutical Co Ltd (Taiho), a subsidiary of Otsuka Group develops and markets pharmaceutical products in the field of cancer, allergy, immunology, urology and others. Its product portfolio includes pharmaceutical products such as anti-allergic agents, anti-tumor agents, H2 receptor …
  • Mazagon Dock Shipbuilders Ltd:戦略・SWOT・企業財務分析
    Mazagon Dock Shipbuilders Ltd - Strategy, SWOT and Corporate Finance Report Summary Mazagon Dock Shipbuilders Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Qu Biologics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Qu Biologics Inc (Qu Biologics) is a developer of immunotherapies designed to restore normal immune function. The company develops site specific immunomodulators that restore the body's innate immune system to treat immune-related diseases and cancer. Its site specific immunotherapy technolo …
  • Esteve Pharmaceuticals SA:企業の戦略的SWOT分析
    Esteve Pharmaceuticals SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Yoho Resources Inc. (YO)-石油・ガス分野:企業M&A・提携分析
    Summary Yoho Resources Inc. (Yoho) is an upstream oil and gas exploration company. The company carries out exploration, development and production of crude oil and natural gas liquid, and natural gas. The company has operations within the Western Canadian Sedimentary Basin focusing exploration activ …
  • HKS Inc:企業の戦略・SWOT・財務情報
    HKS Inc - Strategy, SWOT and Corporate Finance Report Summary HKS Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • ZTE Corporation:企業のM&A・事業提携・投資動向
    ZTE Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's ZTE Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Sensus USA Inc.-エネルギー分野:企業M&A・提携分析
    Summary Sensus USA Inc. (Sensus), a Xylem brand, is a clean technology solutions company that designs and manufactures smart meters, communication systems, and software. It provides smart meters, network technologies, and advanced data analytics solutions. Sensus’s solutions collects data related to …
  • Lee Enterprises Inc (LEE):企業の財務・戦略的SWOT分析
    Lee Enterprises Inc (LEE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • BYD Co Ltd (1211):電力:M&Aディール及び事業提携情報
    Summary BYD Co Ltd (BYD) designs, manufactures and sells rechargeable batteries, photovoltaic products, handset components, and other electronic products. It also offers whole product assembly services. The company manufactures and offers traditional fuel-engine vehicles and new energy vehicles. The …
  • Domino’S Pizza Group Plc
    Domino'S Pizza Group Plc - Strategy, SWOT and Corporate Finance Report Summary Domino'S Pizza Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Brake Bros Foodservice Limited:企業の戦略・SWOT・財務分析
    Brake Bros Foodservice Limited - Strategy, SWOT and Corporate Finance Report Summary Brake Bros Foodservice Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Serodus ASA (SER)-製薬・医療分野:企業M&A・提携分析
    Summary Serodus ASA (Serodus) is a drug development company that focuses on the development of products for unmet medical needs in areas such as diabetes and diabetic comorbidities. The company’s pipeline products include SER150DN, an anti-inflammatory compound under development for diabetic nephrop …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆